Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Bicycle Therapeutics Ltd. unveiled a multi-target collaboration with Genentech Inc. on 25 February under which the UK biotech will employ its proprietary bicyclic peptide platform technology to discover and develop cancer immunotherapies against multiple targets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?